Ludwig Institute For Cancer Research

Ludwig Institute For Cancer Research

Ludwig Institute For Cancer Research

Overview
Date Founded

1971

Headquarters

666 3rd Avenue,28th floor,New York, NY 10017

Charitable Causes

Cancer Research
Medical Research

Employees (Worldwide)

176

Industries

Hospitals & Patient Services
Medical Support Services

Company Description

Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY.

Contact Data
Trying to get in touch with decision makers at Ludwig Institute For Cancer Research? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Executive Director-Technology Development

Executive Vice President-Research

Chief Financial Officer & Secretary

Group Leader

Group Leader

Group Leader

Group Leader

Group Leader

Head, Laboratory of Cancer Genetics

Director, Genomics

Board of Directors

Director, Board Vice Chair at Ludwig Institute For Cancer Research

Founding Director at Stanford Distinguished Careers Institute

Distinguished Alumni
Oliver Bogler is now Chief Operating Officer, Project Echo at University of New Mexico School of Medicine
Yann Echelard is now Operating Partner at Flagship Pioneering
Paths to Ludwig Institute For Cancer Research
Potential Connections via
Relationship Science
You
Ludwig Institute For Cancer Research
Advisors & Consultants
Legal Advisor

Milbank, Tweed, Hadley & McCloy LLP is a global law firm that has provided legal solutions to many of the world’s corporate transactions and litigation. The firm’s transactional capabilities includes capital markets, corporate finance and transactions, project finance, acquisition finance, and other major fields of law practice. Milbank litigation teams resolve disputes involving mergers and acquisitions, proxy battles, financings and securities offerings, intellectual property, white-collar crime, and corporate restructurings, among others.

Clients

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Humanigen, Inc. engages in the development of monoclonal antibodies for various oncology indications and to enhance T-cell therapies. Its lead product candidate is lenzilumab, is a novel humaneered monoclonal antibody. The company was founded on March 15, 2000 and is headquartered in Burlingame, CA.

Key Stats and Financials As of 2016
Market Capitalization
Total Enterprise Value
Earnings Per Share
Revenue
$95.8M
Non-Profit Donations & Grants Received
Investments
Details Hidden

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Suppliers
Memorial Sloan-Kettering Cancer Center Hospitals & Patient Services | New York, NY

Memorial Sloan-Kettering Cancer Center — the world's oldest and largest private cancer center — has devoted more than a century to patient care and innovative research, making significant contributions to better understand, diagnose, and treat cancer. As one of the nation's premier cancer centers, Memorial Sloan-Kettering is one of only 41 institutions in the United States that have been designated Comprehensive Cancer Centers by the National Cancer Institute.

Medidata Solutions, Inc. Pension Funds & Sovereign Wealth | NEW YORK, NY

Welcome to Medidata Solutions. We recognize that our customers' life science research fosters the critically important goals of bringing life-saving and life-enhancing treatments to the public, and we are proud to support this work. Medidata is committed to providing clinical research organizations with the most advanced tools for planning and managing their clinical trials. Our mission is to put innovative technology and insightful data into researchers' hands to help bring treatments to market as safely, efficiently and effectively as possible. The Medidata team has looked at all steps of the clinical trial process—spanning operational and clinical activities—and created solutions for companies of all sizes that use cutting-edge technology, process change management and implementation planning, and robust databases and analytics to take risk, time and resources out of the trial process. By focusing on critical decision-points in clinical research, we are working to develop solutions that provide all members of the research team with novel analytic tools and information technology to maximize their clinical investments

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ludwig Institute For Cancer Research. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ludwig Institute For Cancer Research's profile does not indicate a business or promotional relationship of any kind between RelSci and Ludwig Institute For Cancer Research.